BIOMAT Database Logo BIOMAT Database Logo

Task force #2--the cost of prevention: can we afford it? Can we afford not to do it? 33rd Bethesda Conference. 2002

Harlan M Krumholz, and William S Weintraub, and W David Bradford, and Paul A Heidenreich, and Daniel B Mark, and A David Paltiel
Yale University School of Medicine, New Haven, CT 06520, USA.

UI MeSH Term Description Entries
D011315 Preventive Medicine A medical specialty primarily concerned with prevention of disease (PRIMARY PREVENTION) and the promotion and preservation of health in the individual. Medicine, Preventive,Preventative Care,Preventative Medicine,Preventive Care,Care, Preventative,Care, Preventive,Medicine, Preventative
D002318 Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM. Adverse Cardiac Event,Cardiac Events,Major Adverse Cardiac Events,Adverse Cardiac Events,Cardiac Event,Cardiac Event, Adverse,Cardiac Events, Adverse,Cardiovascular Disease,Disease, Cardiovascular,Event, Cardiac
D003362 Cost-Benefit Analysis A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. In contrast a cost effectiveness in general compares cost with qualitative outcomes. Cost and Benefit,Cost-Benefit Data,Benefits and Costs,Cost Benefit,Cost Benefit Analysis,Cost-Utility Analysis,Costs and Benefits,Economic Evaluation,Marginal Analysis,Analyses, Cost Benefit,Analysis, Cost Benefit,Analysis, Cost-Benefit,Analysis, Cost-Utility,Analysis, Marginal,Benefit and Cost,Cost Benefit Analyses,Cost Benefit Data,Cost Utility Analysis,Cost-Benefit Analyses,Cost-Utility Analyses,Data, Cost-Benefit,Economic Evaluations,Evaluation, Economic,Marginal Analyses
D006291 Health Policy Decisions, usually developed by government policymakers, for determining present and future objectives pertaining to the health care system. Health Care Policies,Health Policies,Healthcare Policy,National Health Policy,Care Policies, Health,Health Care Policy,Health Policy, National,Healthcare Policies,National Health Policies,Policies, Health,Policies, Health Care,Policies, Healthcare,Policy, Health,Policy, Health Care,Policy, Healthcare
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D017048 Health Care Costs The actual costs of providing services related to the delivery of health care, including the costs of procedures, therapies, and medications. It is differentiated from HEALTH EXPENDITURES, which refers to the amount of money paid for the services, and from fees, which refers to the amount charged, regardless of cost. Medical Care Costs,Treatment Costs,Costs, Medical Care,Health Costs,Healthcare Costs,Cost, Health,Cost, Health Care,Cost, Healthcare,Cost, Medical Care,Cost, Treatment,Costs, Health,Costs, Health Care,Costs, Healthcare,Costs, Treatment,Health Care Cost,Health Cost,Healthcare Cost,Medical Care Cost,Treatment Cost

Related Publications

Harlan M Krumholz, and William S Weintraub, and W David Bradford, and Paul A Heidenreich, and Daniel B Mark, and A David Paltiel
Task force #1--magnitude of the prevention problem: opportunities and challenges. 33rd Bethesda Conference.
August 2002, Journal of the American College of Cardiology,
Harlan M Krumholz, and William S Weintraub, and W David Bradford, and Paul A Heidenreich, and Daniel B Mark, and A David Paltiel
Erythropoietin: can we afford to use it? Can we afford not to?
June 2006, Transfusion medicine (Oxford, England),
Harlan M Krumholz, and William S Weintraub, and W David Bradford, and Paul A Heidenreich, and Daniel B Mark, and A David Paltiel
Preventive Cardiology: How can we do Better? Proceedings of the 33rd Bethesda Conference. Bethesda, Maryland, USA. December 18, 2001.
August 2002, Journal of the American College of Cardiology,
Harlan M Krumholz, and William S Weintraub, and W David Bradford, and Paul A Heidenreich, and Daniel B Mark, and A David Paltiel
Task force #3--getting results: who, where, and how? 33rd Bethesda Conference.
August 2002, Journal of the American College of Cardiology,
Harlan M Krumholz, and William S Weintraub, and W David Bradford, and Paul A Heidenreich, and Daniel B Mark, and A David Paltiel
Task force #5--the role of cardiovascular specialists as leaders in prevention: from training to champion. 33rd Bethesda Conference.
August 2002, Journal of the American College of Cardiology,
Harlan M Krumholz, and William S Weintraub, and W David Bradford, and Paul A Heidenreich, and Daniel B Mark, and A David Paltiel
Safety, quality, and performance: can we afford not to do it?
January 2005, Texas medicine,
Harlan M Krumholz, and William S Weintraub, and W David Bradford, and Paul A Heidenreich, and Daniel B Mark, and A David Paltiel
Primary prevention of sudden death with implantable defibrillator therapy in patients with cardiac disease: Can we afford to do it? (Can we afford not to?).
September 2001, Circulation,
Harlan M Krumholz, and William S Weintraub, and W David Bradford, and Paul A Heidenreich, and Daniel B Mark, and A David Paltiel
28th Bethesda Conference. Task Force 2: Guideline implementation.
May 1997, Journal of the American College of Cardiology,
Harlan M Krumholz, and William S Weintraub, and W David Bradford, and Paul A Heidenreich, and Daniel B Mark, and A David Paltiel
34th Bethesda Conference: Task force #4--How do we select patients for atherosclerosis imaging?
June 2003, Journal of the American College of Cardiology,
Harlan M Krumholz, and William S Weintraub, and W David Bradford, and Paul A Heidenreich, and Daniel B Mark, and A David Paltiel
Gold foil-can we afford to do without it?
April 1972, The Journal of the American Academy of Gold Foil Operators,
Copied contents to your clipboard!